Dermatological and gastrointestinal adverse reactions in ocrelizumab treated patients with multiple sclerosis: a case series

20260 citationsJournal Articlegold Open Access

Authors

Lena Höpner · Humboldt-Universität zu Berlin

Ella Marschall · Humboldt-Universität zu Berlin

Patrick Schindler · Humboldt-Universität zu Berlin

Vilmar Frauendorf · Laboclinic (Poland)

Michael Böhmig · Swiss Paraplegic Center

Florian Rakers · LWL-Universitätsklinikum Bochum

Diana Karimi

Abstract

Clinicians should be aware of dermatological and gastrointestinal adverse reactions associated with ocrelizumab, which can develop from a few weeks up to six years after start of therapy.

Topics & Keywords

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Psoriasis: Treatment and Pathogenesis

Publication Details

Published in: Frontiers in Immunology

Volume 17, pp. 1753387-1753387

DOI: 10.3389/fimmu.2026.1753387

Field-Weighted Citation Impact: 0.00

Command Palette

Dermatological and gastrointestinal adverse reactions in ocrelizumab treated patients with multiple sclerosis: a case series

Authors

Abstract

Topics & Keywords

Publication Details